Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing stu...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2024-06-01
|
| Collection: | Translational Oncology |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S193652332400072X |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|